Patents by Inventor Ryosuke Mihara

Ryosuke Mihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEMOLIZUMAB IN THE TREATMENT OF ATOPIC DERMATITIS WITH MODERATE TO SEVERE EXCORIATION
    Publication number: 20260008859
    Abstract: Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Nabil KERROUCHE, Keiko HIROKAWA, Ryosuke MIHARA
  • Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
    Patent number: 12441804
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: October 14, 2025
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
    Patent number: 12435147
    Abstract: Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 7, 2025
    Assignees: Galderma Holding SA, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Nabil Kerrouche, Keiko Hirokawa, Ryosuke Mihara
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
    Publication number: 20240018249
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Application
    Filed: August 8, 2023
    Publication date: January 18, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki lwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
    Publication number: 20230391878
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of uremic pruritus comprising an IL-31 antagonist as an active ingredient.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 7, 2023
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Naoki Fukazawa, Fumie Okada, Tomohisa Saito, Tetsuya Hirahara, Keiko Hirokawa, Ryosuke Mihara
  • Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
    Patent number: 11773173
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 3, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • NEMOLIZUMAB IN THE TREATMENT OF ATOPIC DERMATITIS WITH MODERATE TO SEVERE EXCORIATION
    Publication number: 20200385476
    Abstract: Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 10, 2020
    Inventors: Nabil KERROUCHE, Keiko HIROKAWA, Ryosuke MIHARA
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
    Publication number: 20200102396
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
    Patent number: 10544227
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: January 28, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
    Publication number: 20180079817
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 22, 2018
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa